According to the latest news from Medical Valley, Jiangsu Yahong Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Yahong Pharmaceuticalâ€) has completed more than 100 million RMB B round of financing, led by Longyan Fund, Kaitai Capital, Zhongguancun Qihang Fund and Phoenix Investors and other institutions participate in investment.
Yahong Pharmaceutical was established in March 2010 in Taizhou City, Jiangsu Province, China. Currently, it has clinical research, anti-tumor mechanism research, and business development team in Shanghai Zhangjiang Hi-Tech Park. It has international clinical development and business development in the United States. mechanism. Yahong Pharmaceutical is committed to becoming a new drug research and development enterprise with a certain international influence in the field of anti-tumor and anti-drug infection based on China and globally.
Yahong Pharmaceutical's drug APL-1202 is expected to become the world's first oral treatment for non-muscle invasive bladder cancer. It has received many government grants such as the National Twelfth Five-Year New Drug Creation Project. Clinical treatment through phase II clinical studies has shown that its efficacy is significant, safe, and oral administration, subverting traditional chemotherapy infusion therapy, reducing the pain of cancer treatment. The funds raised in this round will be used primarily to support the rapid clinical trials and drug production of APL-1202 in 40 clinical centers in China, the US Phase II clinical trials and other ongoing research projects to be launched in 2018.
R&D pipeline
“Yahong’s goal is to form the advantages of technology and products in our focused disease treatment field and provide better treatment for Chinese and foreign patients,†said Dr. Pan Ke, Chairman and CEO of Yahong Pharmaceutical. "This round of financing marks that Yahong has entered a new rapid development track in this direction. We are grateful to investors for their recognition and support for Yahong Pharmaceutical's new drug development strategies, projects and technologies."
“Yahong Pharmaceutical's new drug project has breakthrough potential in the field of bladder cancer and multidrug resistance infection at home and abroad,†commented Mr. Yu Zhihua, Chairman of Longyi Capital. "We believe that Yahong team headed by Dr. Pan can fully combine the advantages of domestic and foreign technology, talents, capital and market to make Yahong Pharmaceuticals at home and abroad in the field of anti-tumor and anti-infective treatment, especially urogenital tumors. Leading pharmaceutical company."
Wifi Wireless Baby Monitor,Radio Baby Monitor,Wireless Baby Monitors,Wireless Camera Baby Monitor
Shenzhen Zuomi Technology Co., Ltd. , https://www.zuomicamera.com